Nurix Therapeutics, Inc.
For the period ended May 31, 2025. Filed Jul 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
May 31, 2025 · Filed Jul 9, 2025
NRIX$16.14+5.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share amounts)
| May 31,2025 | November 30,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $84,260 | $109,997 |
| Marketable securities, current | 401,521 | 499,586 |
| Accounts receivable | 19,000 | — |
| Prepaid expenses and other current assets | 10,549 | 9,804 |
| Total current assets | 515,330 | 619,387 |
| Operating lease right-of-use assets | 50,214 | 28,139 |
| Property and equipment, net | 18,773 | 17,757 |
| Restricted cash | 901 | 901 |
| Other assets | 6,337 | 3,159 |
| Total assets | $591,555 | $669,343 |
| Liabilities and stockholdersʼ equity | ||
| Current liabilities: | ||
| Accounts payable | $5,954 | $11,482 |
| Accrued expenses and other current liabilities | 37,005 | 37,994 |
| Operating lease liabilities, current | 5,235 | 8,014 |
| Deferred revenue, current | 27,420 | 38,364 |
| Total current liabilities | 75,614 | 95,854 |
| Operating lease liabilities, net of current portion | 46,696 | 20,289 |
| Deferred revenue, net of current portion | 21,642 | 26,207 |
| Total liabilities | 143,952 | 142,350 |
| Commitments and contingencies (Note 6) | ||
| Stockholdersʼ equity: | ||
| Preferred stock, $0.001 par value— 10,000,000 shares authorized as of May 31, 2025 and November 30, 2024; no shares issued and outstanding as of May 31, 2025 and November 30, 2024 | — | — |
| Common stock, $0.001 par value— 500,000,000 shares authorized as of May 31, 2025 and November 30, 2024; 76,433,664 and 75,870,718 shares issued and outstanding as of May 31, 2025 and November 30, 2024, respectively | 76 | 76 |
| Additional paid-in capital | 1,286,131 | 1,265,536 |
| Accumulated other comprehensive income (loss) | (20) | 150 |
| Accumulated deficit | (838,584) | (738,769) |
| Total stockholdersʼ equity | 447,603 | 526,993 |
| Total liabilities and stockholdersʼ equity | $591,555 | $669,343 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.